

Edgar Filing: AMPLIDYNE INC - Form 10QSB

AMPLIDYNE INC  
Form 10QSB  
August 18, 2003

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549  
FORM 10-QSB

- QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2003.
- TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934.

FOR THE TRANSITION PERIOD FROM \_\_\_\_\_ TO \_\_\_\_\_

Commission File Number 0-21931

AMPLIDYNE, INC.  
(Exact name of small business issuer as specified in its charter)

DELAWARE -----	22-3440510 -----
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

59 LaGrange Street  
Raritan, New Jersey 08869  
(Address of principal executive offices)

(908) 253-6870  
(Issuer's telephone number)

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes X No  
--- ---

The number of shares outstanding of the Issuer's Common Stock, \$.0001 Par Value, as of July 31, 2003 was 10,376,500.

AMPLIDYNE, INC.  
FORM 10-QSB  
SIX MONTHS ENDED JUNE 30, 2003

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION

Item 1 Financial Statements (Unaudited):

Balance Sheets.....	1-2
Statements of Operations.....	3

Edgar Filing: AMPLIDYNE INC - Form 10QSB

Statement of Cash Flows.....4

Statement of Changes in Stockholder's Equity.....5

Notes to Financial Statements.....6-11

Item 2 Management's Discussion and Analysis of Financial  
Condition and Results of Operations.....12-15

Item 3. Controls and Procedures.....15

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.....16

Signatures.....17

Certification.....18

Exhibit 99.1.....19

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

AMPLIDYNE, INC.  
BALANCE SHEETS (UNAUDITED)

ASSETS

	June 20 -----
CURRENT ASSETS	
Cash and cash equivalents	\$
Accounts receivable, net of allowance for doubtful accounts of \$186,000 and \$143,000 in 2003 and 2002, respectively	24
Inventories	90
Loan receivable - officer	
Prepaid expenses and other	3
	-----
Total current assets	1,18
PROPERTY AND EQUIPMENT - AT COST	
Machinery and equipment	72
Furniture and fixtures	4
Autos and trucks	6
Leasehold improvements	
	-----
	84
Less accumulated depreciation and amortization	(77)
	-----
	6
	-----
SECURITY DEPOSITS AND OTHER NON-CURRENT ASSETS	4
	-----

Edgar Filing: AMPLIDYNE INC - Form 10QSB

TOTAL ASSETS \$ 1,29  
=====

Note: The balance sheet at December 31, 2002 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

The accompanying notes are an integral part of these financial statements  
-1-

AMPLIDYNE, INC.  
BALANCE SHEETS (UNAUDITED)

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES

Overdraft  
Current maturities of lease obligations  
Customer advances  
Accounts payable  
Accrued expenses  
Accrued settlement of litigation  
Loans payable - officers

Total current liabilities  
Convertible notes payable

TOTAL LIABILITIES

STOCKHOLDERS' EQUITY

Common stock - authorized, 25,000,000 shares of \$.0001 par value;  
shares 10,376,500 and 9,676,500 shares issued and outstanding  
at June 30, 2003 and December 31, 2002, respectively

Additional paid-in capital  
Accumulated deficit

Note: The balance sheet at December 31, 2002 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

The accompanying notes are an integral part of these financial statements  
-2-

Edgar Filing: AMPLIDYNE INC - Form 10QSB

AMPLIDYNE, INC.  
STATEMENTS OF OPERATIONS (UNAUDITED)  
THREE AND SIX MONTHS ENDED JUNE 30

	Three Months Ended June 30	
	2003	2002
	-----	-----
Net sales	\$ 363,904	252,316
Cost of goods sold	278,925	649,778
	-----	-----
Gross profit	84,979	(397,462)
Operating expenses		
Selling, general and administrative	216,940	751,467
Research, engineering and development	97,373	146,719
Litigation settlement costs	--	315,000
	-----	-----
Operating loss	(229,334)	(1,610,648)
Nonoperating income (expenses)		
Interest income and other income	--	780
Interest expense	--	(932)
	-----	-----
Loss before income taxes	(229,334)	(1,610,800)
Provision for income taxes	698	--
	-----	-----
NET LOSS	\$ (230,032)	\$ (1,610,800)
	=====	=====
Net loss per share - basic and diluted	\$ (0.02)	\$ (0.17)
	=====	=====
Weighted average number of shares outstanding	10,143,167	9,673,780
	=====	=====

The accompanying notes are an integral part of these financial statements

-3-

AMPLIDYNE, INC.  
STATEMENTS OF CASH FLOWS (UNAUDITED)  
SIX MONTHS ENDED JUNE 30

	Six 2003
	-----
Cash flows from operating activities:	
Net Loss	\$ (290,22)
	-----
Adjustments to reconcile net loss to net cash used in operating activities	
Depreciation and amortization	14,80
Bad debt expense	43,00
Litigation loss	--
Provision for inventory write-down	--

Edgar Filing: AMPLIDYNE INC - Form 10QSB

Deferred officer compensation	51,41
Other costs paid with restricted common stock	--
Changes in assets and liabilities	
Accounts receivable	148,78
Inventories	22,70
Prepaid expenses and other assets	(5,39)
Customer advances	47,64
Accounts payable and accrued expense	(78,32)
	-----
Total adjustments	244,63
	-----
Net cash provided (used) for operating activities	(45,59)
	-----
Cash flows from investing activities:	
Officer loans	--
Change in security deposits	1,15
	-----
Net cash provided by (used for) investing activities	1,15
	-----
Cash flows from financing activities:	
Payment of lease obligations	(2,04)
Officer loans	21,00
Proceeds from convertible promissory note	20,00
Proceeds from sale of common stock, net of costs	--
Subscriptions receivable preferred stock - net	--
	-----
Net cash provided by financing activities	38,95
	-----
NET INCREASE (DECREASE) IN CASH	(5,48)
Cash (overdraft) and cash equivalents beginning of period	(11,93)
	-----
Cash (overdraft) and cash equivalents at end of period	\$ (17,42)
	=====
Supplemental disclosures of cash flow information:	
Cash paid for: Interest	\$ --
Income taxes	\$ 69

The accompanying notes are an integral part of these financial statements

-4-

AMPLIDYNE, INC.  
STATEMENT OF STOCKHOLDERS' EQUITY  
YEAR ENDED DECEMBER 31, 2002 AND SIX MONTHS ENDED JUNE 30, 2003

	Preferred Stock	
	Shares	Par Value
	-----	-----
BALANCE AT DECEMBER 31, 2001	55,000	\$ 6
Net loss for the year ended December 31, 2002		
Cost of litigation to be settled by the issuance of common stock		
Collection of subscription receivable		
Issuance of common stock in settlement of class action		
Issuance of common stock, net of costs		
Conversion of preferred stock to common stock	(55,000)	(6)
Issuance of common stock for services rendered by third party		

Edgar Filing: AMPLIDYNE INC - Form 10QSB

BALANCE AT DECEMBER 31, 2002	-----	-----
	--	--
Net loss for the six months ended June 30, 2003		
Issuance of common stock in connection with litigation settlement	-----	-----
	-----	-----
BALANCE AT JUNE 30, 2003	--	\$ --
	=====	=====
	Additional	Accumulated
	Paid-In	Deficit
	Capital	-----
	-----	-----
BALANCE AT DECEMBER 31, 2001	\$ 21,921,495	\$ (19,569,652)
Net loss for the year ended December 31, 2002		(2,380,027)
Cost of litigation to be settled by the issuance of common stock	29,400	
Collection of subscription receivable		
Issuance of common stock in settlement of class action	(32)	
Issuance of common stock, net of costs	539,925	
Conversion of preferred stock to common stock	(64)	
Issuance of common stock for services rendered by third party	4,200	--
	-----	-----
BALANCE AT DECEMBER 31, 2002	22,494,924	(21,949,679)
Net loss for the six months ended June 30, 2003		(290,222)
Issuance of common stock in connection with litigation settlement	(70)	
	-----	-----
BALANCE AT JUNE 30, 2003	\$ 22,494,854	\$ (22,239,901)
	=====	=====

The accompanying notes are an integral part of these financial statements

-5-

AMPLIDYNE, INC.  
NOTES TO UNAUDITED INTERIM FINANCIAL STATEMENTS  
JUNE 30, 2003

NOTE A - ADJUSTMENTS

In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of (a) results of operations for the six and three month periods ended June 30, 2003 and 2002 (b) the financial position at June 30, 2003 (c) the statements of cash flows for the six and three month period ended June 30, 2003 and 2002, and (d) the changes in stockholders' equity for the three month period ended June 30, 2003 have been made. The results of operations for the three and six months ended June 30, 2003 are not necessarily indicative of the results to be expected for the full year.

NOTE B - UNAUDITED INTERIM FINANCIAL INFORMATION

The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for financial statements. For further information, refer to the audited financial statements and notes

## Edgar Filing: AMPLIDYNE INC - Form 10QSB

thereto for the year ended December 31, 2002 included in the Company's Form 10-KSB filed with the Securities and Exchange Commission on April 15, 2003.

The Company's financial statements have been presented on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The liquidity of the Company has been adversely affected in recent years by significant losses from operations. As further discussed in Note F, the Company incurred losses of \$290,222 for the six months ended June 30, 2003, has no cash and has seen its working capital decline by \$254,271 to \$163,804 since the beginning of the fiscal year. Current liabilities exceed cash and receivables by \$770,211 indicating that the Company will have difficulty meeting its financial obligations for the balance of this fiscal year. These factors raise substantial doubt as to the Company's ability to continue as a going concern. Recently, operations have been funded by loans from the Chief Executive Officer and costs have been cut through substantial reductions in labor and operations.

As further discussed in Note F, management is seeking additional financing and intends to aggressively market its products, control operating costs and broaden its product base through enhancements of products. The Company believes that these measures may provide sufficient liquidity for it to continue as a going concern in its present form. Accordingly, the financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amount and classification of liabilities or any other adjustments that might be necessary should the Company be unable to continue as a going concern in its present form.

-6-

AMPLIDYNE, INC.  
NOTES TO UNAUDITED INTERIM FINANCIAL STATEMENTS  
JUNE 30, 2003

NOTE C - STOCKHOLDERS' EQUITY

At June 30, 2003, the following 945,000 warrants, remained outstanding:

- (1) 20,000 exercisable at \$1.00 through May 2010
- (2) 20,000 exercisable at \$7.00 through December 2004
- (3) 30,000 exercisable at \$6.00 through November 2004
- (4) 50,000 exercisable at \$2.00 through December 2004
- (5) 50,000 exercisable at \$4.00 through December 2004
- (6) 16,000 exercisable at \$1.75 through December 2004
- (7) 41,500 exercisable at \$1.80 through July 31, 2004
- (8) 207,500 exercisable at \$3.00 through July 31, 2004
- (9) 55,000 exercisable at \$1.20 through September 30, 2004
- (10) 300,000 exercisable at \$2.00 through December 31, 2005
- (11) 75,000 exercisable at \$.96 through March 2007
- (12) 80,000 exercisable at \$1.50 through December 2004.

At June 30, 2003, the Company had employee stock options outstanding to acquire 2,251,000 shares of common stock at exercise prices of \$0.15 to \$4.00.

During the first quarter ended March 31, 2003, the Company issued 700,000 shares of the Company's restricted common stock to High Gain Antenna Co., Ltd. of Korea (see Note E.4.) in connection with the settlement of the litigation.

## Edgar Filing: AMPLIDYNE INC - Form 10QSB

In March 2003, two stockholders loaned the Company \$10,000 each under a Convertible Promissory Note due in March 2005, with interest, due at maturity, of 6%. The note is convertible into restricted common stock at the rate of \$.10 per share.

During the first quarter ended March 31, 2003, the Company re-priced and extended employee stock options to certain employees as follows: officers and directors, 1,150,000 options re-priced from \$4.00 to \$0.15 and extended to May 2006; all other employees 145,000 options re-priced from \$4.00 to \$0.15 and extended to May 2006. Additionally, the Vice President of Operations has been granted an additional 200,000 options at \$0.15 and expiring in May 2006.

### NOTE D - LOSS PER SHARE

The Company complies with the requirements of the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 128, "Earnings per Share" ("SFAS No. 128"). SFAS No. 128 specifies the compilation, presentation and disclosure requirements for earnings per share for entities with publicly held common stock or potential common stock. Net loss per common share - basic and diluted is determined by dividing the net loss by the weighted average number of common stock outstanding.

Net loss per common share - diluted does not include potential common shares derived from stock options and warrants (see Note C) because they are antidilutive.

-7-

AMPLIDYNE, INC.  
NOTES TO UNAUDITED INTERIM FINANCIAL STATEMENTS  
JUNE 30, 2003

### NOTE E - LITIGATION

>From time to time, the Company is party to what it believes are routine litigation and proceedings that may be considered as part of the ordinary course of its business. Except for the proceedings noted below, the Company is not aware of any pending litigation or proceedings that could have a material effect on the Company's results of operations or financial condition.

The Company is a party to the following matters:

1. AIRNET COMMUNICATIONS CORPORATION VS AMPLIDYNE, INC.

AirNet filed a complaint in the Circuit Court of the Eighteenth Judicial District of the State of Florida on January 23, 1997 alleging breach of contract. During 2000, the Company settled with AirNet at a cost of \$175,000; \$25,000 is to be paid quarterly over two years. \$95,000 remained unpaid at June 30, 2003.

2. ENS ENGINEERING VS AMPLIDYNE, INC.

The Company was also a defendant in a complaint filed in the United States District Court for the District of New Jersey on May 13, 1998. The complaint alleges breach of contract of a representative agreement between the Company and ENS Engineering of South Korea. The Company reached oral settlement terms and, based upon such oral settlement, the court dismissed the case in the first quarter of 2000. The terms of the oral settlement called for the Company to pay \$85,000 in twelve equal monthly installments, none of which has been paid as of December 31, 2000. The Company has not received any required documents and



## Edgar Filing: AMPLIDYNE INC - Form 10QSB

releases from ENS. The financial statements do not include any provision for this settlement.

3. The Company was subject to a SEC formal order of investigation relating to the subject matter of the Class Action Lawsuit that was commenced in 1999 and settled in 2001. On May 22, 2003, the Commission filed a settled action in the United States District Court for the District of New Jersey against Amplidyne, Inc. ("Amplidyne") and its President, Chairman and Chief Executive Officer, Devendar S. Bains ("Bains"). The Commission's Complaint alleges that Amplidyne and Bains violated the antifraud provision of the federal securities laws by making false statements concerning Amplidyne's purported entry into the high-speed Internet wireless access market. Simultaneously with the filing of the Complaint, Amplidyne and Bains, without admitting or denying the allegations in the Complaint, consented to the entry of a final judgment permanently enjoining both from violating Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder. In addition, Bains agreed to pay a civil penalty of \$50,000.

#### 4. HIGH GAIN ANTENNA CO., LTD. OF KOREA

The Company (as well as an officer and director of the Company) was a defendant in a complaint brought in the Superior Court of New Jersey, Law Division, Somerset County, by High Gain Antenna Co., Ltd. of Korea in November 2000. The complaint sought damages for an alleged breach of a contract for the repair of certain equipment purchased by plaintiff from a distributor of the Company's products and the Company. A trial commenced on May 7, 2002, and on May 13, 2002, the jury brought in a verdict against the Company for \$400,000. The Company had filed a motion in the Law Division for a new trial, which was denied and gave notice of appeal to file an appeal of the verdict and judgment to the Superior Court of New Jersey, Appellate Division. Management later determined

-8-

AMPLIDYNE, INC.  
NOTES TO UNAUDITED INTERIM FINANCIAL STATEMENTS  
JUNE 30, 2003

that pursuing the appeal would not be in the best interest of the Company and its shareholders.

In January 2003, the Company entered into a Stipulation of Settlement and Release before the Superior Court of New Jersey, Somerset County. The settlement stipulates that the Company pay a total of \$200,000 plus 700,000 shares of restricted common stock of the Company valued by the agreement at \$105,000 (management has determined that the discounted value of the 700,000 restricted shares was \$29,400 in January 2003 based on quoted market price of \$0.07 per share discounted for lack of marketability). The stipulation calls for an initial payment of \$75,000 (paid in March 2003) with the remaining balance payable in \$25,000 increments on the following dates: June 2, 2003, August 31, 2003, November 29, 2003, February 27, 2004 and May 28, 2004. The record judgement of \$400,000 shall remain until the payment obligations are made in full. In the event of default, the plaintiff shall have the right to execute the judgement after crediting \$105,000 for the agreed value of the shares issued plus any payments made pursuant to the settlement. Accordingly, failure by the Company to timely meet the settlement terms will have a material adverse effect on the Company's financial position and prospects.

#### 5. AMPLIDYNE, INC. V. WAYNE FOGEL, DIGITAL COMMUNICATIONS NETWORK, INC. AND INTERNET NETWORK CORPORATION

## Edgar Filing: AMPLIDYNE INC - Form 10QSB

On May 30, 2002, the Company filed a two count lawsuit against the above mentioned defendants in the Superior Court of New Jersey, Law Division, Somerset County, seeking, among other things, declaratory relief that the Company is not obligated to pay a finders fee (in connection with the Company's purchase of the Darwin Assets), and that the Company is entitled to monetary damages as a result of defendant's misrepresentations. On July 10, 2002, the matter was removed to the United States District Court of New Jersey but later transferred to the United States Bankruptcy Court and then transferred back to the United States District Court of New Jersey. On July 29, 2002, defendants filed a counterclaim seeking \$200,000 in damages as a result of a finders fee agreement. In January 2003, the matter was transferred to the United States District Court for the Middle District of Florida. The defendants sought a further transfer to the United States Bankruptcy Court for the Middle District of Florida, but such motion was denied. Internet Network Corporation has a pending motion seeking sanctions against the Company for violating the bankruptcy automatic stay for actions against debtors in bankruptcy proceedings. Although the Company is confident in its position, it cannot predict the outcome of the case and any negative outcome may have a material adverse effect on the Company's financial position or prospects.

### NOTE F - LIQUIDITY

The Company's financial statements have been presented on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The liquidity of the Company has been adversely affected in recent years by significant losses from operations. The Company has incurred losses of \$290,222 and \$2,113,580 for the six months ended June 30, 2003 and 2002, respectively.

With no remaining cash and no near term prospects of private placements, options or warrant exercises and reduced revenues, management believes that the Company will have great difficulty meeting its working capital and litigation settlement obligations over the next 12 months. The Company is

-9-

### AMPLIDYNE, INC. NOTES TO UNAUDITED INTERIM FINANCIAL STATEMENTS JUNE 30, 2003

presently dependent on cash flows generated from sales and loans from officers to meet our obligations. Our failure to consummate a merger with an appropriate partner or to substantially improve our revenues will have serious adverse consequences and, accordingly, there is substantial doubt in our ability to remain in business over the next 12 months. There can be no assurance that any financing will be available to the Company on acceptable terms, or at all. If adequate funds are not available, the Company may be required to delay, scale back or eliminate its research, engineering and development or manufacturing programs or obtain funds through arrangements with partners or others that may require the Company to relinquish rights to certain of its technologies or potential products or other assets. Accordingly, the inability to obtain such financing could have a material adverse effect on the Company's business, financial condition and results of operations.

Management's plans for dealing with the foregoing matters include:

- o Increasing sales of its high speed internet connectivity products through both individual customers, strategic alliances and mergers.
- o Decreasing the dependency on certain major customers by aggressively

## Edgar Filing: AMPLIDYNE INC - Form 10QSB

seeking other customers in the amplifier markets;

o Partnering with significant companies to jointly develop innovative products, which has yielded orders with multinational companies to date, and which are expected to further expand such relationships;

o Reducing costs through a more streamlined operation by using automated machinery to produce components for our products;

o Deferral of payments of officers' salaries, as needed;

o Selling remaining net operating losses applicable to the State of New Jersey, pursuant to a special government high-technology incentive program in order to provide working capital, if possible;

o Reducing overhead costs and general expenditures.

o Merging with another company to provide adequate working capital and jointly develop innovative products.

### NOTE G - OTHER COMMENTS

#### 1. Officer Loans

As of June 30, 2003, the Company owes \$110,974 to the Chief Executive Officer for loans and unpaid salaries. During the six months ended June 30, 2003, the Chief Executive Officer advanced \$101,000 to the Company and was repaid \$80,000. During the six months ended June 30, 2003 salaries of \$51,416 were deferred.

#### 2. Advance payments from customer

In March 2003, a customer advanced \$100,000 to the Company for future orders. These orders began shipping in April 2003. The remaining balance of this advance at June 30, 2003 is \$47,641.

-10-

AMPLIDYNE, INC.  
NOTES TO UNAUDITED INTERIM FINANCIAL STATEMENTS  
JUNE 30, 2003

### NOTE H - SEGMENT INFORMATION

The Company commenced its wireless Internet connectivity business in the summer of 2000. The Company does not measure its operating results, assets or liabilities by segment. However, the following limited segment information is available:

	Six Months Ended June 30 2003	Six Months Ended June 30 2002	Year Ended December 31, 2002
	-----	-----	-----
Sales - external			
Amplifier	\$ 743,274	406,708	\$ 992,361
Internet business	130,238	350,240	621,371
	-----	-----	-----
	\$ 873,512	\$ 756,948	\$1,613,732
	=====	=====	=====

## Edgar Filing: AMPLIDYNE INC - Form 10QSB

Inventory		--	
Amplifier	\$ 409,317	\$ 467,765	\$ 441,654
Internet business	494,688	462,562	485,059
	-----	-----	-----
	\$ 904,005	\$ 930,327	\$ 926,713
	=====	=====	=====

-11-

AMPLIDYNE, INC.

### PART I - FINANCIAL INFORMATION

#### ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

RESULTS OF OPERATIONS - THE THREE MONTHS ENDED JUNE 30, 2003 COMPARED TO THREE MONTHS ENDED JUNE 30, 2002.

Revenues for the three months ended June 30, 2003 increased by \$111,588 from \$252,316 to \$363,904, or 44% compared to the three months ended June 30, 2002. The sales increases were primarily in amplifiers. Coupled with the staff reductions and other aggressive cost cuts, this quarter's losses were reduced compared with the first 3 quarters of last year.

The majority of the amplifier sales for the three months ended June 30, 2003 were obtained from the Wireless Local Loop amplifier products to a major European customer. The Company has also supplied 3.5GHz linear amplifiers to its major North American customer. Sales of amplifiers were approximately 82.6% of total sales compared to 57% of total sales for the same period last year. The Ampwave high speed wireless Internet products and broadband solutions accounted for approximately 17.4% of total sales, against 43% of total sales for the same period last year.

The Company has continued to develop and refine its amplifier products for the wireless communications market. The Company has also refined its wireless internet amplifiers for the indoor market. Sales and marketing efforts have been focused in the more stable United States, European and Canadian markets.

Cost of sales was \$278,925 or 77% of sales compared to 258% during the same period for 2002. The cost of sales for same quarter last year included an inventory write-down of \$233,995 representing 93% of sales for that quarter. Gross margin for the three months ended June 30, 2003 amounted to a profit of \$92,745 (25%) compared to a loss of \$397,462 (160%), for the same period ended June 30, 2002. The improvement in gross margin was principally due to improved production efficiency from staff reductions over the past 3 quarters. The Company is continuing to assess cost reduction and is promoting increased product demand to improve gross margins in 2003.

Selling, general and administrative expenses (excluding stock based compensation) decreased in 2003 by \$534,527 to \$216,940 from \$751,467, in 2002. Expressed as a percentage of sales, the selling, general and administrative expenses (excluding stock based compensation) were 25% in 2003 and 99% in 2002. The principal factors contributing to the decrease in selling, general and administrative expenses were related to the effects of our cost cutting program implemented in the 3rd and 4th quarters of 2002. In the quarter ended June 30, 2003, we continued to maintain the lower staffing and overhead levels that we instituted in 2002.

## Edgar Filing: AMPLIDYNE INC - Form 10QSB

Research, engineering and development expenses were 27% of net sales for the three months ended June 30, 2003 compared to 58% in 2002. In 2003 and 2002, the principal activity of the business related to the design and production of product for OEM manufacturers, particularly for the IMT 2000 and 3.5 GHz single channel products and refinements to the High Speed Internet products. The research, engineering and development expenses consist principally of salary cost for engineers and the expenses of equipment purchases specifically for the design and testing of the prototype products. The Company's research and development efforts are influenced by available funds and the level of effort required by the engineering

-12-

### AMPLIDYNE, INC.

staff on customer specific projects.

The Company had interest income and other income in 2002 of \$3,052 due to influx of new capital during 2000 and 2001 from our private placements and exercise of warrants and options. Interest income went down to \$NIL in 2003 because our cash balances which we have historically temporarily invested in interest bearing accounts have been fully depleted.

As a result of the foregoing, the Company incurred net losses of \$230,032 or \$0.02 per share for the quarter ended June 30, 2003 compared with net losses of \$1,610,800 or \$0.17 per share for the same quarter in 2002.

RESULTS OF OPERATIONS - THE SIX MONTHS ENDED JUNE 30, 2003 COMPARED TO SIX MONTHS ENDED JUNE 30, 2002.

Revenues for the six months ended June 30, 2003 increased by \$116,564 from \$756,948 to \$873,512, or 15% compared to the six months ended June 30, 2002. Coupled with the staff reductions and other aggressive cost cuts, the first six months losses were reduced compared with the first six months of last year.

The majority of the amplifier sales for the six months ended June 30, 2003 were obtained from the Wireless Local Loop amplifier products to a major European customer. The Company has also supplied 3.5GHz linear amplifiers to its major North American customer.

The Company has continued to develop and refine its amplifier products for the wireless communications market. The Company has also refined its wireless internet amplifiers for the indoor market. Sales and marketing efforts have been focused in the more stable United States, European and Canadian markets.

Cost of sales was \$557,783 or 64% of sales compared to \$1,029,890 or 136% of sales during the same period for 2002. The cost of sales for same period last year included an inventory write-down of \$233,995 representing 31% of sales for that period. The improvement in gross margin was principally due to and due improved production efficiency from staff reductions over the past 3 quarters. The Company is continuing to assess cost reduction and is promoting increased product demand to improve gross margins in 2003.

Selling, general and administrative expenses (excluding stock based compensation) decreased in 2003 by \$826,129 to \$410,671 from \$1,236,800, in 2002. Expressed as a percentage of sales, the selling, general and administrative expenses (excluding stock based compensation) were 47% in 2003 and 163% in 2002. The principal factors contributing to the decrease in selling, general and administrative expenses were related to the effects of our cost cutting program implemented in the 3rd and 4th quarters of 2002. In the quarter

## Edgar Filing: AMPLIDYNE INC - Form 10QSB

ended June 30, 2003, we continued to maintain the lower staffing and overhead levels that we instituted in 2002.

Research, engineering and development expenses were 22% of net sales for the six months ended June 30, 2003 compared to 38% in 2002. In 2003 and 2002, the principal activity of the business related to the design and production of product for OEM manufacturers, particularly for the IMT 2000 and 3.5 GHz single channel products and refinements to the High Speed Internet products. The research, engineering and development expenses consist principally of salary cost for engineers and the expenses of equipment purchases specifically for the design and testing of the prototype products. The Company's research and development efforts are influenced by available funds and the level of effort required by the engineering

-13-

AMPLIDYNE, INC.

staff on customer specific projects.

The Company had interest income and other income in 2002 of \$3,052 due to influx of new capital during 2000 and 2001 from our private placements and exercise of warrants and options. Interest income went down to \$NIL in 2003 because our cash balances which we have historically temporarily invested in interest bearing accounts have been fully depleted.

As a result of the foregoing, the Company incurred net losses of \$290,222 or \$0.03 per share for the six months ended June 30, 2003 compared with net losses of \$2,113,580 or \$0.23 per share for the same period in 2002.

### LIQUIDITY AND CAPITAL RESOURCES

Liquidity refers to our ability to generate adequate amounts of cash to meet our needs. We have been generating the cash necessary to fund our operations from continual loans from the President and Chief Executive Officer of the Company, Devendar Bains. We have incurred a loss in each year since inception. We expect to incur further losses, that the losses may fluctuate, and that such fluctuations may be substantial. As of June 30, 2003 we had an accumulated deficit of \$22,239,901. Potential immediate sources of liquidity are loans from Mr. Bains. Another potential source of liquidity is the sale of restricted shares of our common stock, but there are no immediate plans for such sale.

As of June 30, 2003, our current liabilities exceeded our cash and receivables by \$770,211. Our current ratio was 1.16 to 1.00, but our ratio of accounts receivable to current liabilities was only 0.24 to 1.00. This indicates that we will have difficulty meeting our obligations as they come due. We are carrying \$904,005 in inventory, of which \$625,842 represents component parts. Based on year to date usage, we are carrying 348 days worth of parts inventory. Because of the lead times in our manufacturing process, we will likely need to replenish many items before we use everything we now have in stock. Accordingly, we will need more cash to replenish our component parts inventory before we are able realize cash from all of our existing inventories.

As of June 30, 2003, we had an overdraft of \$17,420 compared to an overdraft of \$11,939 at December 31, 2002. Overall our cash and cash equivalents decreased \$29,359 during 2003. Our cash used for operating actives was \$45,591 This year we received loans of \$21,000 and deferred salary payments to officer/stockholders of \$51,416. We also received proceeds from the issuance of convertible promissory notes of \$20,000.

## Edgar Filing: AMPLIDYNE INC - Form 10QSB

The allowance for doubtful accounts on trade receivables increased from \$143,000 (25% of accounts receivable of \$583,506) in 2002 to \$186,000 (43% of accounts receivable of \$434,722) in 2003. Because of our relatively small number of customers and low sales volume, accounts receivable balances and allowances for doubtful accounts do not reflect a consistent relationship to sales. We determine our allowance for doubtful accounts based on a specific customer-by-customer review of collectibility.

Our inventories decreased by \$22,708 to \$904,005 in 2003 compared to \$926,713 at December 31, 2002, a decrease of 2%.

The Company has several lease obligations for its premises and certain equipment requiring minimum monthly payments of approximately \$9,800 through 2005. Although the Company did not convert salaries to officers through the issuance of Common Stock in 2003 or 2002, it may do so in 2003. To help alleviate the cash flow difficulties, the Chief Executive Officer and the Vice President of Operations agreed to additional salary deferrals of \$19,666 and \$10,000, respectively.

-14-

AMPLIDYNE, INC.

The Company continues to explore strategic relationships with ISP's, customers and others, which could involve jointly developed products, revenue-sharing models, investments in or by the Company, or other arrangements. There can be no assurance that a strategic relationship can be consummated.

In the past, the officers of the Company have deferred a portion of their salaries or provided loans to the Company to meet short-term liquidity requirements. Where possible, the Company has issued stock or granted warrants to certain vendors in lieu of cash payments, and may do so in the future. There can be no assurance that any additional financing will be available to the Company on acceptable terms, or at all. If adequate funds are not available, the Company may be required to delay, scale back or eliminate its research, engineering and development or manufacturing programs or obtain funds through arrangements with partners or others that may require the Company to relinquish rights to certain of its technologies or potential products or other assets. Accordingly, the inability to obtain such financing could have a material adverse effect on the Company's business, financial condition and results of operations.

With no remaining cash and no near term prospects of private placements, options or warrant exercises and reduced revenues, we believe that we will have great difficulty meeting our working capital and litigation settlement obligations over the next 12 months. We are presently dependent on cash flows generated from sales and loans from officers to meet our obligations. Our failure to consummate a merger, or substantially improve our revenues will have serious adverse consequences and, accordingly, there is substantial doubt in our ability to remain in business over the next 12 months. There can be no assurance that any financing will be available to the Company on acceptable terms, or at all. If adequate funds are not available, the Company may be required to delay, scale back or eliminate its research, engineering and development or manufacturing programs or obtain funds through arrangements with partners or others that may require the Company to relinquish rights to certain of its technologies or potential products or other assets. Accordingly, the inability to obtain such financing could have a material adverse effect on the Company's business, financial condition and results of operations.

ITEM 3. CONTROLS AND PROCEDURES

Edgar Filing: AMPLIDYNE INC - Form 10QSB

(a) Evaluation of Disclosure Controls and Procedures.

Within the 90 days prior to the date of this report, Amplidyne, Inc. carried out an evaluation, under the supervision and with the participation of the Company's management, including the Company's Chief Executive and Principal Accounting Officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures pursuant to Exchange Act Rule 13a-14. Based upon that evaluation, the Chief Executive and Principal Accounting Officer concluded that the Company's disclosure controls and procedures are effective in timely alerting him to material information required to be included in the Company's periodic SEC filings relating to the Company.

(b) Changes in Internal Controls.

There were no significant changes in the Company's internal controls or in other factors that could significantly affect these internal controls subsequent to the date of my most recent evaluation.

-15-

AMPLIDYNE, INC.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

See Note E to the Company's financial statements set forth in Part I.

-16-

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AMPLIDYNE, INC.

Dated: August 14, 2003

By: /s/ Devendar S. Bains  
-----  
Name: Devendar S. Bains  
Title: Chief Executive Officer,  
  
Treasurer,  
Principal Accounting  
Officer and Director

-17-

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL ACCOUNTING  
OFFICER PURSUANT TO 18 U.S.C 1350, AS ADOPTED, AND  
THE REQUIREMENTS OF SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Devendar S. Bains, Chief Executive Officer and Principal Accounting Officer of Amplidyne, Inc. (the "Company") do hereby certify that:



Edgar Filing: AMPLIDYNE INC - Form 10QSB

1. I have reviewed this quarterly report on Form 10-QSB of the Company;
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report; and
3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the period presented in this quarterly report.
4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the Company and have:
  - (a) designed such disclosure controls and procedures to ensure that material information relating to the Company, is made known to me by others within the Company, particularly during the period in which this quarterly report is being prepared;
  - (b) evaluated the effectiveness of the Company's disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the "Evaluation Date"); and
  - (c) presented in this quarterly report my conclusions about the effectiveness of the disclosure controls and procedures based on my evaluation as of the Evaluation Date;
5. I have disclosed, based on my most recent evaluation, to the Company's auditors and the audit committee of the Company's board of directors (or persons performing the equivalent functions):
  - (a) all significant deficiencies in the design or operation of internal controls which could adversely affect the Company's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and
  - (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal controls; and
6. I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of my most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

/s/ Devendar S. Bains

-----  
Devendar S. Bains  
Chief Executive Officer and  
Principal Accounting Officer

August 14, 2003